Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology

January 26, 2017
Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight global director of content, how the company is rebranding itself from its former incarnation ProNAI Therapeutics, armed with two in-licensed assets focused on DNA damage repair (DDR) and USD 100 million in the bank.
Previous Video
Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates
Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates

In the six months after joining Arena Pharmaceuticals as CEO, Dr. Amit Munshi has been busy: reducing the c...

Next Video
Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery
Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery

Having ditched RNA silencing in 2012, PhaseRx president and CEO Dr. Robert Overell explains to Mike Ward, g...